Clinical Trials Logo

Clinical Trial Summary

The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).


Clinical Trial Description

The primary specific aim is to evaluate the use of intranasal scopolamine gel (DPI-386) and sensory augmentation (SA) as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. The proposed sensory augmentation will utilize vibrotactile feedback of pitch and roll tilt using a portable belt (Engineering Acoustics, Inc.). The investigators will utilize exposure to simulated capsule wave motion on a 6DOF platform to provide an operationally relevant platform to induce motion sickness and impair performance on functional tasks. The investigators hypothesize that the combination of intranasal scopolamine gel and sensory augmentation of Earth vertical will be more effective to mitigate motion sickness and improve task performance than when administered separately. Using a randomized double-blind cross-over design, the investigators will compare motion sickness symptom severity and time to endpoint (symptom level defined as severe malaise) in 30 subjects during exposure to simulated wave motion on a 6DOF platform inside of a crew capsule mockup. The investigators will compare four conditions: (1) intranasal scopolamine gel (0.4 mg) with sensory augmentation, (2) intranasal scopolamine gel (0.4 mg) without sensory augmentation, (3) placebo control with sensory augmentation, and (4) placebo control without sensory augmentation. The wave motion stressor will begin 30 min post drug administration and will not exceed 45 min in duration. Performance on a series of functional tasks (dual-task tracking and eye-hand target acquisition) will be performed pre, during, immediately post, and following 15 min of recovery of each test. The bioavailability of scopolamine for each session will be estimated from plasma concentrations obtained at drug administration and then every 15 min up to 2-hr post-dosage. Subjective side effects and performance on the Psychomotor Vigilance Test (PVT) will also be obtained at 15 min intervals. A small pilot study including 10 subjects tested once each will be performed to verify the experimental protocol including that the simulated capsule wave motion will provoke motion sickness symptoms. These pilot sessions will not include the medication nor the blood sampling. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05886660
Study type Interventional
Source Repurposed Therapeutics, Inc.
Contact Barry Feinberg, MD
Phone 314-697-1330
Email bfeinberg@defenderpharma.com
Status Recruiting
Phase Phase 2
Start date January 21, 2022
Completion date September 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT06128707 - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed NCT05611814 - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms N/A
Recruiting NCT06106256 - Three-Axis Wearable Adaptive Vestibular Stimulator N/A
Completed NCT02839135 - A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Phase 1
Completed NCT04420949 - Sensory Training for Visual Motion Sickness N/A
Completed NCT04184115 - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Phase 3
Completed NCT03988530 - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Phase 3
Terminated NCT04219982 - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Phase 2/Phase 3
Terminated NCT02155309 - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Phase 2/Phase 3
Completed NCT04947423 - Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion Phase 3
Recruiting NCT05903924 - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Recruiting NCT04999449 - Nebulizer Delivery of Intranasal Scopolamine Phase 1
Completed NCT03755596 - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Phase 4
Recruiting NCT05628220 - Motion Sickness Desensitization Using VR N/A
Recruiting NCT06138613 - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Completed NCT04327661 - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Phase 3
Completed NCT06232785 - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients Phase 4
Completed NCT06056622 - Motion Sickness Rehabilitation for Virtual Reality N/A
Withdrawn NCT04331561 - Sensory Training for Orientation and Balance N/A